Deep Medicine Acquisition Profit Margin

The latest profit margin for DMAQ is -55.68% as of June 2026. That compares with -52.55% in the prior-year period — down 5.9% year over year. That is below the sector sector average of 13.23%. Investors often review this figure alongside Deep Medicine Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAQ's profit margin moved from -52.55% to -55.68% — a 5.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Deep Medicine Acquisition's valuation or profitability profile.

Against its sector companies, DMAQ currently prints -55.68% for profit margin, while the sector average sits near 13.23%. That is roughly 521.0% below the sector mean. Large gaps often invite a closer look at Deep Medicine Acquisition's growth, margins, and balance sheet.

Profit Margin shows how effectively Deep Medicine Acquisition converts resources into returns. At -55.68%, DMAQ may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -52.55% in the prior-year period — down 5.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting DMAQ's profit margin (-55.68%), review year-over-year change from -52.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.